RhumbLine Advisers’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

RhumbLine Advisers’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-606,023	Closed	-$537K	–	2988
2022 Q4	$537K	Buy	606,023 +48,432	+9%	+$64.2K	﹤0.01%	2431
2022 Q3	$875K	Buy	557,591 +34,728	+7%	+$78.8K	﹤0.01%	2209
2022 Q2	$1.05M	Buy	522,863 +213,161	+69%	+$369K	﹤0.01%	2115
2022 Q1	$722K	Buy	309,702 +5,297	+2%	+$16.5K	﹤0.01%	2270
2021 Q4	$1.42M	Buy	304,405 +5,653	+2%	+$35.1K	﹤0.01%	2063
2021 Q3	$2.28M	Buy	298,752 +7,335	+3%	+$62.2K	﹤0.01%	1837
2021 Q2	$2.82M	Buy	291,417 +8,903	+3%	+$70.9K	﹤0.01%	1772
2021 Q1	$2.34M	Sell	282,514 -11,518	-4%	-$122K	﹤0.01%	1841
2020 Q4	$2.01M	Buy	294,032 +44,853	+18%	+$360K	﹤0.01%	1844
2020 Q3	$2.78M	Sell	249,179 -14,082	-5%	-$129K	﹤0.01%	1507
2020 Q2	$1.65M	Buy	263,261 +100,296	+62%	+$384K	﹤0.01%	1835
2020 Q1	$300K	Sell	162,965 -809	-0.5%	-$2.33K	﹤0.01%	2408
2019 Q4	$554K	Buy	163,774 +6,998	+4%	+$16.7K	﹤0.01%	2316
2019 Q3	$336K	Buy	156,776 +1,140	+0.7%	+$2.66K	﹤0.01%	2523
2019 Q2	$416K	Buy	155,636 +16,188	+12%	+$58.3K	﹤0.01%	2438
2019 Q1	$662K	Buy	139,448 +1,811	+1%	+$4.75K	﹤0.01%	2201
2018 Q4	$330K	Buy	137,637 +54,072	+65%	+$177K	﹤0.01%	2491
2018 Q3	$368K	Buy	83,565 +3,873	+5%	+$21.5K	﹤0.01%	2410
2018 Q2	$574K	Buy	+79,692	New	+$542K	﹤0.01%	2242
2017 Q2	–	Sell	-34,686	Closed	-$137K	–	2972
2017 Q1	$137K	Buy	34,686 +2,686	+8%	+$13.5K	﹤0.01%	2736
2016 Q4	$157K	Buy	32,000 +1,725	+6%	+$10.4K	﹤0.01%	2729
2016 Q3	$234K	Buy	30,275 +300	+1%	+$2.02K	﹤0.01%	2602
2016 Q2	$168K	Buy	29,975 +575	+2%	+$3.67K	﹤0.01%	2811
2016 Q1	$158K	Buy	29,400 +230	+0.8%	+$1.34K	﹤0.01%	2810
2015 Q4	$254K	Buy	29,170 +4,110	+16%	+$34.7K	﹤0.01%	2672
2015 Q3	$210K	Buy	25,060 +1,110	+5%	+$17.7K	﹤0.01%	2763
2015 Q2	$422K	Buy	+23,950	New	+$308K	﹤0.01%	2443

Other funds holding SRNE

Paloma Partners Greenwich, Connecticut $1.36B AUM 249.29% 1-Year Est. Return

OCM

Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return

OFA

Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return

CGA

Crescent Grove Advisors Lake Forest, Illinois $1.2B AUM 23.08% 1-Year Est. Return

LCM

Lattice Capital Management Kirkland, Washington $49.5M AUM 28.58% 1-Year Est. Return

STB

S&T Bank Indiana, Pennsylvania $333M AUM 106.39% 1-Year Est. Return

GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return

HFRG

Houlihan Financial Resource Group Ashburn, Virginia $281M AUM 17.68% 1-Year Est. Return

VFA

Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return

GBWM

Granite Bay Wealth Management Portsmouth, New Hampshire $1.09B AUM 22.93% 1-Year Est. Return

RhumbLine Advisers's SRNE Position: Q1 2023 in Review

RhumbLine Advisers sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2023, closing a stake of 606,023 shares — an estimated $537K sold.

RhumbLine Advisers first reported a position in SRNE in Q2 2015 and held it in 27 quarters. The position peaked at $2.82M in Q2 2021. 34 funds tracked by Wall St. Rank hold SRNE as of Q1 2023.

RhumbLine Advisers reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
RhumbLine Advisers sold 606,023 Sorrento Therapeutics, Inc. shares in Q1 2023, an estimated $537K.
RhumbLine Advisers first reported a position in Sorrento Therapeutics, Inc. in Q2 2015 and held it in 27 quarters.
RhumbLine Advisers's Sorrento Therapeutics, Inc. position peaked at $2.82M in Q2 2021.
34 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2023.

Based on RhumbLine Advisers's 13F filing for Q1 2023, filed 11 May 2023.